P
Pierre Leblanc
Researcher at Harvard University
Publications - 38
Citations - 1886
Pierre Leblanc is an academic researcher from Harvard University. The author has contributed to research in topics: Induced pluripotent stem cell & Stem cell. The author has an hindex of 16, co-authored 33 publications receiving 1375 citations. Previous affiliations of Pierre Leblanc include Boston Children's Hospital & McLean Hospital.
Papers
More filters
Journal ArticleDOI
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang,Jianping Yuan,Elda Righi,Walid S. Kamoun,Marek Ancukiewicz,Jean Nezivar,Michael Santosuosso,John D. Martin,Margaret R. Martin,Fabrizio Vianello,Pierre Leblanc,Lance L. Munn,Peigen Huang,Dan G. Duda,Dai Fukumura,Rakesh K. Jain,Mark C. Poznansky +16 more
TL;DR: It is demonstrated that targeting tumor vasculature with lower vascular-normalizing doses, but not high antivascular/antiangiogenic doses, of an anti-VEGF receptor 2 (VEGFR2) antibody results in a more homogeneous distribution of functional tumor vessels.
Journal ArticleDOI
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease.
Jeffrey Schweitzer,Bin Song,Todd M. Herrington,Tae-Yoon Park,Nayeon Lee,Sanghyeok Ko,Jeha Jeon,Young Joo Cha,Kyungsang Kim,Quanzheng Li,Claire Henchcliffe,Michael G. Kaplitt,Carolyn Neff,Otto Rapalino,Hyemyung Seo,In-Hee Lee,Jisun Kim,Taewoo Kim,Gregory A. Petsko,Jerome Ritz,Bruce M. Cohen,Sek Won Kong,Pierre Leblanc,Bob S. Carter,Kwang-Soo Kim +24 more
TL;DR: Clinical measures of symptoms of Parkinson's disease after surgery stabilized or improved at 18 to 24 months after implantation, and positron-emission tomography with the use of fluorine-18-L-dihydroxyphenylalanine suggested graft survival.
Journal ArticleDOI
CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer
Elda Righi,Satoshi Kashiwagi,Jianping Yuan,Michael Santosuosso,Pierre Leblanc,Rachel Ingraham,Benjamin Forbes,Beth Edelblute,Brian Collette,Deyin Xing,Magdalena Kowalski,Magdalena Kowalski,Maria Cristina Mingari,Fabrizio Vianello,Michael J. Birrer,Sandra Orsulic,Sandra Orsulic,Glenn Dranoff,Mark C. Poznansky +18 more
TL;DR: Modulation of the CXCL12/CXCR4 axis in ovarian cancer has multimodal effects on tumor pathogenesis associated with induction of antitumor immunity and offers a definitive preclinical validation of CX CR4 as a therapeutic target in this disease.
Journal ArticleDOI
Human autologous iPSC–derived dopaminergic progenitors restore motor function in Parkinson’s disease models
Bin Song,Young Joo Cha,Sanghyeok Ko,Jeha Jeon,Nayeon Lee,Hyemyung Seo,Hyemyung Seo,Kyungjoon Park,In-Hee Lee,Claudia Lopes,Melissa Feitosa,Maria Jose Luna,Jin Hyuk Jung,Jisun Kim,Jisun Kim,Dabin Hwang,Bruce M. Cohen,Martin H. Teicher,Pierre Leblanc,Bob S. Carter,Jeffrey H. Kordower,Vadim Y. Bolshakov,Sek Won Kong,Jeffrey Schweitzer,Kwang Soo Kim +24 more
TL;DR: A platform of core techniques for the production of mDA progenitors as a safe and effective therapeutic product is reported and it is proposed that this platform is suitable for the successful implementation of human personalized autologous cell therapy for PD.
Journal ArticleDOI
Pluripotent stem cell-based therapy for Parkinson’s disease: Current status and future prospects
Kai C. Sonntag,Bin Song,Nayeon Lee,Jin Hyuk Jung,Young Joo Cha,Pierre Leblanc,Carolyn Neff,Sek Won Kong,Bob S. Carter,Jeffrey Schweitzer,Kwang-Soo Kim +10 more
TL;DR: The prospects and challenges of human pluripotent stem cell-based cell therapy for PD are discussed, leading to tremendous advancement in understanding of these novel classes of stem cells and promising great potential for regenerative medicine.